FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890737184> ?p ?o ?g. }

• W2890737184 endingPage "1389" @default.
• W2890737184 startingPage "1383" @default.
• W2890737184 abstract "•Type III hyperlipoproteinemia is a highly atherogenic dyslipoproteinemia. •Type III cannot be diagnosed from a conventional lipid panel. •Type III can be diagnosed based on total cholesterol, triglyceride, and apoB •Total cholesterol and triglyceride can be lower in type III than commonly thought. •Type III may be more common than commonly thought. Background Type III hyperlipoproteinemia is a highly atherogenic dyslipoproteinemia characterized by hypercholesterolemia and hypertriglyceridemia due to markedly increased numbers of cholesterol-enriched chylomicron and very-low-density lipoprotein (VLDL) remnant lipoprotein particles. Type III can be distinguished from mixed hyperlipidemia based on a simple diagnostic algorithm, which involves total cholesterol, triglycerides, and apolipoprotein B (apoB). However, apoB is not measured routinely. Objective The objective of the present study was to determine if patients with type III could be distinguished from mixed hyperlipidemia based on lipoprotein lipids. Methods Classification was based first on total cholesterol and triglyceride and then on the apoB diagnostic algorithm using apoB plus total cholesterol plus triglycerides, and validated by sequential ultracentrifugation. Four hundred and forty normals, 637 patients with hypertriglyceridemia, and 714 with hypertriglyceridemia and hypercholesterolemia were studied. Plasma lipoproteins were separated by sequential ultracentrifugation and heparin-manganese precipitation. Cholesterol, triglyceride, and apoB were measured in plasma and isolated lipoprotein fractions. Results Of the 1351 patients with hypertriglyceridemia, 49 had type III hyperlipoproteinemia, as diagnosed by the apoB algorithm and validated by ultracentrifugation. Plasma triglycerides were higher in the type III subjects: 4.16 mmol/L (3.35–6.08, 25th–75th percentile), but there was considerable overlap with the hypertriglyceridemic subjects 2.65 mmol/L (1.91–4.20, 25th–75th percentile) and the combined hyperlipidemic subjects 3.02 mmol/L (2.07–5.32, 25th–75th percentile). Similarly, total cholesterol was 4.79 mmol/L (4.31–5.58, 25th–75th percentile) for type III vs 5.5 mmol/L (4.64–5.78, 25th–75th percentile) and 7.02 mmol/L (6.39–7.96, 25th–75th percentile), respectively. By contrast, as identified by the apoB algorithm, the VLDL-C/TG, VLDL-C/VLDL-TG, VLDL-C/VLDL apoB, and VLDL apoB/LDL apoB ratios were all higher in type III than in the other hypertriglyceridemic dyslipoproteinemias with the exception of type V as diagnosed by the apoB algorithm. Conclusion Cholesterol and triglycerides cannot reliably distinguish type III hyperlipoproteinemia from mixed hyperlipidemia. Adding apoB and applying the apoB algorithm makes reliable diagnosis possible and easy. However, unless apoB is introduced into routine clinical care, type III hyperlipoproteinemia will often not be recognized. Given the cardiovascular risk associated with type III and its responsiveness to treatment, this should not be acceptable. Type III hyperlipoproteinemia is a highly atherogenic dyslipoproteinemia characterized by hypercholesterolemia and hypertriglyceridemia due to markedly increased numbers of cholesterol-enriched chylomicron and very-low-density lipoprotein (VLDL) remnant lipoprotein particles. Type III can be distinguished from mixed hyperlipidemia based on a simple diagnostic algorithm, which involves total cholesterol, triglycerides, and apolipoprotein B (apoB). However, apoB is not measured routinely. The objective of the present study was to determine if patients with type III could be distinguished from mixed hyperlipidemia based on lipoprotein lipids. Classification was based first on total cholesterol and triglyceride and then on the apoB diagnostic algorithm using apoB plus total cholesterol plus triglycerides, and validated by sequential ultracentrifugation. Four hundred and forty normals, 637 patients with hypertriglyceridemia, and 714 with hypertriglyceridemia and hypercholesterolemia were studied. Plasma lipoproteins were separated by sequential ultracentrifugation and heparin-manganese precipitation. Cholesterol, triglyceride, and apoB were measured in plasma and isolated lipoprotein fractions. Of the 1351 patients with hypertriglyceridemia, 49 had type III hyperlipoproteinemia, as diagnosed by the apoB algorithm and validated by ultracentrifugation. Plasma triglycerides were higher in the type III subjects: 4.16 mmol/L (3.35–6.08, 25th–75th percentile), but there was considerable overlap with the hypertriglyceridemic subjects 2.65 mmol/L (1.91–4.20, 25th–75th percentile) and the combined hyperlipidemic subjects 3.02 mmol/L (2.07–5.32, 25th–75th percentile). Similarly, total cholesterol was 4.79 mmol/L (4.31–5.58, 25th–75th percentile) for type III vs 5.5 mmol/L (4.64–5.78, 25th–75th percentile) and 7.02 mmol/L (6.39–7.96, 25th–75th percentile), respectively. By contrast, as identified by the apoB algorithm, the VLDL-C/TG, VLDL-C/VLDL-TG, VLDL-C/VLDL apoB, and VLDL apoB/LDL apoB ratios were all higher in type III than in the other hypertriglyceridemic dyslipoproteinemias with the exception of type V as diagnosed by the apoB algorithm. Cholesterol and triglycerides cannot reliably distinguish type III hyperlipoproteinemia from mixed hyperlipidemia. Adding apoB and applying the apoB algorithm makes reliable diagnosis possible and easy. However, unless apoB is introduced into routine clinical care, type III hyperlipoproteinemia will often not be recognized. Given the cardiovascular risk associated with type III and its responsiveness to treatment, this should not be acceptable." @default.
• W2890737184 created "2018-09-27" @default.
• W2890737184 creator A5001305262 @default.
• W2890737184 creator A5014267007 @default.
• W2890737184 creator A5034080261 @default.
• W2890737184 creator A5046862139 @default.
• W2890737184 creator A5081548605 @default.
• W2890737184 creator A5087425230 @default.
• W2890737184 date "2018-11-01" @default.
• W2890737184 modified "2023-10-18" @default.
• W2890737184 title "The spectrum of type III hyperlipoproteinemia" @default.
• W2890737184 cites W2004353849 @default.
• W2890737184 cites W2054328698 @default.
• W2890737184 cites W2059802803 @default.
• W2890737184 cites W2060615057 @default.
• W2890737184 cites W2072755464 @default.
• W2890737184 cites W2081834793 @default.
• W2890737184 cites W2107874108 @default.
• W2890737184 cites W2121423297 @default.
• W2890737184 cites W2135142672 @default.
• W2890737184 cites W2135503869 @default.
• W2890737184 cites W2148986433 @default.
• W2890737184 cites W2168725511 @default.
• W2890737184 cites W2756375940 @default.
• W2890737184 cites W2800713945 @default.
• W2890737184 doi "https://doi.org/10.1016/j.jacl.2018.09.006" @default.
• W2890737184 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30318453" @default.
• W2890737184 hasPublicationYear "2018" @default.
• W2890737184 type Work @default.
• W2890737184 sameAs 2890737184 @default.
• W2890737184 citedByCount "36" @default.
• W2890737184 countsByYear W28907371842018 @default.
• W2890737184 countsByYear W28907371842019 @default.
• W2890737184 countsByYear W28907371842020 @default.
• W2890737184 countsByYear W28907371842021 @default.
• W2890737184 countsByYear W28907371842022 @default.
• W2890737184 countsByYear W28907371842023 @default.
• W2890737184 crossrefType "journal-article" @default.
• W2890737184 hasAuthorship W2890737184A5001305262 @default.
• W2890737184 hasAuthorship W2890737184A5014267007 @default.
• W2890737184 hasAuthorship W2890737184A5034080261 @default.
• W2890737184 hasAuthorship W2890737184A5046862139 @default.
• W2890737184 hasAuthorship W2890737184A5081548605 @default.
• W2890737184 hasAuthorship W2890737184A5087425230 @default.
• W2890737184 hasConcept C11772777 @default.
• W2890737184 hasConcept C126322002 @default.
• W2890737184 hasConcept C134018914 @default.
• W2890737184 hasConcept C2776919658 @default.
• W2890737184 hasConcept C2778163477 @default.
• W2890737184 hasConcept C2778913445 @default.
• W2890737184 hasConcept C2779091943 @default.
• W2890737184 hasConcept C2780072125 @default.
• W2890737184 hasConcept C555293320 @default.
• W2890737184 hasConcept C62746215 @default.
• W2890737184 hasConcept C71924100 @default.
• W2890737184 hasConcept C8243546 @default.
• W2890737184 hasConceptScore W2890737184C11772777 @default.
• W2890737184 hasConceptScore W2890737184C126322002 @default.
• W2890737184 hasConceptScore W2890737184C134018914 @default.
• W2890737184 hasConceptScore W2890737184C2776919658 @default.
• W2890737184 hasConceptScore W2890737184C2778163477 @default.
• W2890737184 hasConceptScore W2890737184C2778913445 @default.
• W2890737184 hasConceptScore W2890737184C2779091943 @default.
• W2890737184 hasConceptScore W2890737184C2780072125 @default.
• W2890737184 hasConceptScore W2890737184C555293320 @default.
• W2890737184 hasConceptScore W2890737184C62746215 @default.
• W2890737184 hasConceptScore W2890737184C71924100 @default.
• W2890737184 hasConceptScore W2890737184C8243546 @default.
• W2890737184 hasIssue "6" @default.
• W2890737184 hasLocation W28907371841 @default.
• W2890737184 hasLocation W28907371842 @default.
• W2890737184 hasOpenAccess W2890737184 @default.
• W2890737184 hasPrimaryLocation W28907371841 @default.
• W2890737184 hasRelatedWork W1885316912 @default.
• W2890737184 hasRelatedWork W1966237146 @default.
• W2890737184 hasRelatedWork W2025648868 @default.
• W2890737184 hasRelatedWork W2029164903 @default.
• W2890737184 hasRelatedWork W2121788140 @default.
• W2890737184 hasRelatedWork W2129790693 @default.
• W2890737184 hasRelatedWork W2155529975 @default.
• W2890737184 hasRelatedWork W2155947160 @default.
• W2890737184 hasRelatedWork W2162381401 @default.
• W2890737184 hasRelatedWork W1975118316 @default.
• W2890737184 hasVolume "12" @default.
• W2890737184 isParatext "false" @default.
• W2890737184 isRetracted "false" @default.
• W2890737184 magId "2890737184" @default.
• W2890737184 workType "article" @default.